Announcements

As all of the articles published in Cancers (ISSN: 2072-6694) are open access, you have free and unlimited access to the full text of all articles. We welcome you to read our most highly cited papers published in 2023 in the Section “Cancer Immunology and Immunotherapy”, which are listed below:

1. “Extracellular Vesicles in Triple–Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential”
by Kaushik Das, Subhojit Paul, Arnab Ghosh, Saurabh Gupta, Tanmoy Mukherjee, Prem Shankar, Anshul Sharma, Shiva Keshava, Subhash C. Chauhan, Vivek Kumar Kashyap et al.
Cancers 2023, 15(19), 4879; https://doi.org/10.3390/cancers15194879
Available online: https://www.mdpi.com/2072-6694/15/19/4879

2. “Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy”
by Neta Bar-Hai, Guy Ben-Betzalel, Ronen Stoff, Shirly Grynberg, Jacob Schachter, Ronnie Shapira-Frommer and Nethanel Asher
Cancers 2023, 15(11), 3041; https://doi.org/10.3390/cancers15113041
Available online: https://www.mdpi.com/2072-6694/15/11/3041

3. “Cytokine Profile in Lung Cancer Patients: Anti-Tumor and Oncogenic Cytokines”
by Freddy Elad Essogmo, Angelina V. Zhilenkova, Yvan Sinclair Ngaha Tchawe, Abah Moses Owoicho, Alexander S. Rusanov, Alexander Boroda, Yuliya N. Pirogova, Zaiana D. Sangadzhieva, Varvara D. Sanikovich, Nikolay N. Bagmet et al.
Cancers 2023, 15(22), 5383; https://doi.org/10.3390/cancers15225383
Available online: https://www.mdpi.com/2072-6694/15/22/5383

4. “Role of Oxidative Stress in Metabolic Reprogramming of Brain Cancer”
by Kirti Agrawal, Shailendra Asthana and Dhruv Kumar
Cancers 2023, 15(20), 4920; https://doi.org/10.3390/cancers15204920
Available online: https://www.mdpi.com/2072-6694/15/20/4920

5. “TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies”
by Md Faqrul Hasan, Tayler J. Croom-Perez, Jeremiah L. Oyer, Thomas A. Dieffenthaller, Liza D. Robles-Carrillo, Jonathan E. Eloriaga, Sanjana Kumar, Brendan W. Andersen and Alicja J. Copik
Cancers 2023, 15(10), 2712; https://doi.org/10.3390/cancers15102712
Available online: https://www.mdpi.com/2072-6694/15/10/2712

6. “Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults”
by Meagan Mandabach Olivet, Michael C. Brown, Zachary J. Reitman, David M. Ashley, Gerald A. Grant, Yuanfan Yang and James M. Markert
Cancers 2023, 15(15), 3901; https://doi.org/10.3390/cancers15153901
Available online: https://www.mdpi.com/2072-6694/15/15/3901

7. “Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs”
by Elin M. V. Forsberg, Rebecca Riise, Sara Saellström, Joakim Karlsson, Samuel Alsén, Valentina Bucher, Akseli E. Hemminki, Roger Olofsson Bagge, Lars Ny, Lisa M. Nilsson et al.
Cancers 2023, 15(3), 648; https://doi.org/10.3390/cancers15030648
Available online: https://www.mdpi.com/2072-6694/15/3/648

8. “Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes?”
by Jonathan Thouvenin, Claire Masson, Philippe Boudier, Denis Maillet, Sabine Kuchler-Bopp, Philippe Barthélémy and Thierry Massfelder
Cancers 2023, 15(3), 793; https://doi.org/10.3390/cancers15030793
Available online: https://www.mdpi.com/2072-6694/15/3/793

9. “Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation”
by Eleonora Sosa Cuevas, Philippe Saas and Caroline Aspord
Cancers 2023, 15(8), 2206; https://doi.org/10.3390/cancers15082206
Available online: https://www.mdpi.com/2072-6694/15/8/2206

10. “Bispecific Antibodies in Hematological Malignancies: A Scoping Review”
by Mohamed H. Omer, Areez Shafqat, Omar Ahmad, Khaled Alkattan, Ahmed Yaqinuddin and Moussab Damlaj
Cancers 2023, 15(18), 4550; https://doi.org/10.3390/cancers15184550
Available online: https://www.mdpi.com/2072-6694/15/18/4550

11. “B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma”
by Cristina Bottino, Chiara Vitale, Alessandra Dondero and Roberta Castriconi
Cancers 2023, 15(13), 3279; https://doi.org/10.3390/cancers15133279
Available online: https://www.mdpi.com/2072-6694/15/13/3279

12. “FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer”
by Peter Grell, Simona Borilova, Pavel Fabian, Iveta Selingerova, David Novak, Petr Muller, Igor Kiss and Rostislav Vyzula
Cancers 2023, 15(6), 1901; https://doi.org/10.3390/cancers15061901
Available online: https://www.mdpi.com/2072-6694/15/6/1901

13. “Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines”
by Elisabetta Mereu, Damiano Abbo, Tina Paradzik, Michela Cumerlato, Cecilia Bandini, Maria Labrador, Monica Maccagno, Domenica Ronchetti, Veronica Manicardi, Antonino Neri et al.
Cancers 2023, 15(8), 2199; https://doi.org/10.3390/cancers15082199
Available online: https://www.mdpi.com/2072-6694/15/8/2199

14. “Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy”
by Aleksandra Basek, Grzegorz K. Jakubiak, Grzegorz Cieślar and Agata Stanek
Cancers 2023, 15(24), 5786; https://doi.org/10.3390/cancers15245786
Available online: https://www.mdpi.com/2072-6694/15/24/5786

15. “Clinical Application of ImmunoPET Targeting Checkpoint Inhibitors”
by Elisabetta Maria Abenavoli, Flavia Linguanti, Raffaella Calabretta, Roberto C. Delgado Bolton, Valentina Berti and Egesta Lopci
Cancers 2023, 15(23), 5675; https://doi.org/10.3390/cancers15235675
Available online: https://www.mdpi.com/2072-6694/15/23/5675

You are invited to view and submit relevant papers to the journal Cancers.

Cancers Editorial Office